210:
31:
336:
408:
Targeting tumor hypoxia in cancer treatment aims to overcome radiotherapy resistance of hypoxic tumors. Thus, a major clinical implication for F-EF5-PET imaging is expected to be guiding of radiotherapy dose modulation. Clinical studies on F-EF5-PET/CT imaging have indicated clinically acceptable
413:
also favorable imaging characteristics, prognostic value and repeatability. A recent 18F-EF5-PET/MR study showed promising potential in detecting tumor hypoxia in cervical cancer. However, F-EF5-PET/CT is not feasible in imaging of ovarian cancer due to physiological intra-abdominal
710:
Komar G, Lehtiö K, Seppänen M, Eskola O, Levola H, Lindholm P, et al. (November 2014). "Prognostic value of tumour blood flow, EF5 and FDG PET/CT imaging in patients with head and neck cancer treated with radiochemotherapy".
626:
Lin LL, Silvoniemi A, Stubbs JB, Rengan R, Suilamo S, Solin O, et al. (September 2012). "Radiation dosimetry and biodistribution of the hypoxia tracer (18)F-EF5 in oncologic patients".
583:
Ziemer LS, Evans SM, Kachur AV, Shuman AL, Cardi CA, Jenkins WT, et al. (February 2003). "Noninvasive imaging of tumor hypoxia in rats using the 2-nitroimidazole 18F-EF5".
349:
803:
Narva, Sara I.; Seppänen, Marko P.; Raiko, Juho R.H.; Forsback, Sarita J.; Orte, Katri J.; Virtanen, Johanna M.; Hynninen, Johanna; Hietanen, Sakari (December 2021).
111:
382:
Non-labeled EF5 has been extensively used in immunohistochemical studies for several years and its hypoxia specificity has been comprehensively evaluated The
249:
431:
Evans SM, Fraker D, Hahn SM, Gleason K, Jenkins WT, Jenkins K, et al. (March 2006). "EF5 binding and clinical outcome in human soft tissue sarcomas".
559:
909:
542:
Koch CJ (2002). "[1] Measurement of absolute oxygen levels in cells and tissues using oxygen sensors and 2-nitroimidazole EF5".
466:
Lord EM, Harwell L, Koch CJ (December 1993). "Detection of hypoxic cells by monoclonal antibody recognizing 2-nitroimidazole adducts".
224:
414:
F-EF5-accumulation. Further studies evaluating the clinical use of F-EF5 PET imaging in head and neck cancer are ongoing.
394:
167:
188:
356:
914:
754:
Silvoniemi A, Suilamo S, Laitinen T, Forsback S, Löyttyniemi E, Vaittinen S, et al. (February 2018).
390:
544:
Measurement of absolute oxygen levels in cells and tissues using oxygen sensors and 2-nitroimidazole EF5
17:
410:
43:
205:
77:
736:
692:
661:
Komar G, Seppänen M, Eskola O, Lindholm P, Grönroos TJ, Forsback S, et al. (December 2008).
608:
233:
InChI=1S/C8H7F5N4O3/c9-7(10,8(11,12)13)4-15-5(18)3-16-2-1-14-6(16)17(19)20/h1-2H,3-4H2,(H,15,18)
854:"The feasibility of [F]EF5-PET/CT to image hypoxia in ovarian tumors: a clinical study"
885:
834:
826:
785:
728:
684:
643:
600:
565:
555:
524:
475:
448:
387:
756:"Repeatability of tumour hypoxia imaging using [F]EF5 PET/CT in head and neck cancer"
875:
865:
816:
775:
767:
720:
674:
635:
592:
547:
514:
506:
440:
402:
272:
131:
87:
176:
209:
880:
853:
780:
755:
519:
494:
372:
327:
852:
Laasik M, Hynninen J, Forsback S, Noponen T, Seppänen M, Hietanen S (September 2020).
551:
375:
derivative used in oncology research. Due to its similarity in chemical structure to
903:
510:
696:
612:
740:
401:
and several other malignant tumors. This can help show how a tumor will respond to
398:
156:
821:
804:
444:
383:
376:
870:
771:
724:
679:
662:
596:
312:
122:
830:
889:
838:
789:
732:
688:
647:
604:
569:
528:
452:
30:
639:
479:
663:"18F-EF5: a new PET tracer for imaging hypoxia in head and neck cancer"
143:
326:
Except where otherwise noted, data are given for materials in their
805:"Imaging of Tumor Hypoxia With 18F-EF5 PET/MRI in Cervical Cancer"
110:
100:
546:. Methods in Enzymology. Vol. 352. Elsevier. pp. 3–31.
433:
International
Journal of Radiation Oncology, Biology, Physics
193:
760:
European
Journal of Nuclear Medicine and Molecular Imaging
713:
European
Journal of Nuclear Medicine and Molecular Imaging
585:
European
Journal of Nuclear Medicine and Molecular Imaging
393:
of EF5 is being studied for its possibility to be used in
495:"Optimizing hypoxia detection and treatment strategies"
344:
155:
409:biodistribution and dosimetric profile, and in
86:
8:
628:Cancer Biotherapy & Radiopharmaceuticals
208:
130:
22:
879:
869:
820:
779:
678:
518:
379:, EF5 binds in cells displaying hypoxia.
175:
397:(PET) to detect low levels of oxygen in
423:
254:
229:
204:
56:-(2,2,3,3,3-pentafluoropropyl)acetamide
236:Key: JGGDSDPOPRWSCX-UHFFFAOYSA-N
7:
146:
257:O=()c1nccn1CC(=O)NCC(F)(F)C(F)(F)F
14:
511:10.1053/j.semnuclmed.2014.10.004
493:Koch CJ, Evans SM (March 2015).
334:
296:
290:
284:
29:
330:(at 25 °C , 100 kPa).
302:
278:
1:
552:10.1016/s0076-6879(02)52003-6
822:10.1097/RLU.0000000000003914
499:Seminars in Nuclear Medicine
445:10.1016/j.ijrobp.2005.05.068
395:positron emission tomography
667:Journal of Nuclear Medicine
931:
910:Diagnostic medical imaging
871:10.1186/s13550-020-00689-z
15:
809:Clinical Nuclear Medicine
772:10.1007/s00259-017-3857-3
725:10.1007/s00259-014-2818-3
680:10.2967/jnumed.108.053785
597:10.1007/s00259-002-1037-5
324:
265:
245:
220:
70:
62:
42:
37:
28:
640:10.1089/cbr.2011.1130
411:head and neck cancer
44:Preferred IUPAC name
16:For other uses, see
320: g·mol
25:
357:Infobox references
23:
561:978-0-12-182255-2
365:Chemical compound
363:
362:
189:CompTox Dashboard
112:Interactive image
922:
894:
893:
883:
873:
849:
843:
842:
824:
800:
794:
793:
783:
751:
745:
744:
707:
701:
700:
682:
658:
652:
651:
623:
617:
616:
580:
574:
573:
539:
533:
532:
522:
490:
484:
483:
463:
457:
456:
428:
347:
341:
338:
337:
319:
304:
298:
292:
286:
280:
273:Chemical formula
213:
212:
197:
195:
179:
159:
148:
134:
114:
90:
65:NSC-684681; EF-5
52:-imidazol-1-yl)-
33:
26:
930:
929:
925:
924:
923:
921:
920:
919:
915:Nitroimidazoles
900:
899:
898:
897:
858:EJNMMI Research
851:
850:
846:
815:(12): 952–957.
802:
801:
797:
753:
752:
748:
719:(11): 2042–50.
709:
708:
704:
673:(12): 1944–51.
660:
659:
655:
625:
624:
620:
582:
581:
577:
562:
541:
540:
536:
492:
491:
487:
468:Cancer Research
465:
464:
460:
430:
429:
425:
420:
366:
359:
354:
353:
352: ?)
343:
339:
335:
331:
317:
307:
301:
295:
289:
283:
275:
261:
258:
253:
252:
241:
238:
237:
234:
228:
227:
216:
198:
191:
182:
162:
149:
137:
117:
104:
93:
80:
66:
58:
57:
21:
12:
11:
5:
928:
926:
918:
917:
912:
902:
901:
896:
895:
844:
795:
766:(2): 161–169.
746:
702:
653:
618:
575:
560:
534:
485:
474:(23): 5721–6.
458:
422:
421:
419:
416:
373:nitroimidazole
364:
361:
360:
355:
333:
332:
328:standard state
325:
322:
321:
315:
309:
308:
305:
299:
293:
287:
281:
276:
271:
268:
267:
263:
262:
260:
259:
256:
248:
247:
246:
243:
242:
240:
239:
235:
232:
231:
223:
222:
221:
218:
217:
215:
214:
206:DTXSID10165114
201:
199:
187:
184:
183:
181:
180:
172:
170:
164:
163:
161:
160:
152:
150:
142:
139:
138:
136:
135:
127:
125:
119:
118:
116:
115:
107:
105:
98:
95:
94:
92:
91:
83:
81:
76:
73:
72:
68:
67:
64:
60:
59:
47:
46:
40:
39:
35:
34:
13:
10:
9:
6:
4:
3:
2:
927:
916:
913:
911:
908:
907:
905:
891:
887:
882:
877:
872:
867:
863:
859:
855:
848:
845:
840:
836:
832:
828:
823:
818:
814:
810:
806:
799:
796:
791:
787:
782:
777:
773:
769:
765:
761:
757:
750:
747:
742:
738:
734:
730:
726:
722:
718:
714:
706:
703:
698:
694:
690:
686:
681:
676:
672:
668:
664:
657:
654:
649:
645:
641:
637:
633:
629:
622:
619:
614:
610:
606:
602:
598:
594:
591:(2): 259–66.
590:
586:
579:
576:
571:
567:
563:
557:
553:
549:
545:
538:
535:
530:
526:
521:
516:
512:
508:
505:(2): 163–76.
504:
500:
496:
489:
486:
481:
477:
473:
469:
462:
459:
454:
450:
446:
442:
438:
434:
427:
424:
417:
415:
412:
406:
404:
400:
396:
392:
389:
385:
380:
378:
374:
370:
358:
351:
346:
329:
323:
316:
314:
311:
310:
277:
274:
270:
269:
264:
255:
251:
244:
230:
226:
219:
211:
207:
203:
202:
200:
190:
186:
185:
178:
174:
173:
171:
169:
166:
165:
158:
154:
153:
151:
145:
141:
140:
133:
129:
128:
126:
124:
121:
120:
113:
109:
108:
106:
102:
97:
96:
89:
85:
84:
82:
79:
75:
74:
69:
61:
55:
51:
45:
41:
36:
32:
27:
19:
861:
857:
847:
812:
808:
798:
763:
759:
749:
716:
712:
705:
670:
666:
656:
634:(7): 412–9.
631:
627:
621:
588:
584:
578:
543:
537:
502:
498:
488:
471:
467:
461:
439:(3): 922–7.
436:
432:
426:
407:
399:brain tumors
388:radiolabeled
381:
368:
367:
71:Identifiers
63:Other names
53:
49:
48:2-(2-Nitro-1
377:etanidazole
266:Properties
88:152721-37-4
904:Categories
864:(1): 103.
418:References
391:derivative
313:Molar mass
177:383HJ2T87O
123:ChemSpider
99:3D model (
78:CAS Number
831:1536-0229
403:treatment
890:32910291
839:34619699
790:29075831
733:24898846
697:16561341
689:18997048
648:22897720
613:22002592
605:12552344
570:12125356
529:25704388
453:16458778
24:18F-EF5
881:7483702
781:5745570
741:6276936
520:4365940
480:8242628
350:what is
348: (
318:302.161
144:PubChem
888:
878:
837:
829:
788:
778:
739:
731:
695:
687:
646:
611:
603:
568:
558:
527:
517:
478:
451:
345:verify
342:
250:SMILES
157:389053
132:344807
38:Names
737:S2CID
693:S2CID
609:S2CID
371:is a
225:InChI
101:JSmol
886:PMID
835:PMID
827:ISSN
786:PMID
729:PMID
685:PMID
644:PMID
601:PMID
566:PMID
556:ISBN
525:PMID
476:PMID
449:PMID
168:UNII
18:EF-5
876:PMC
866:doi
817:doi
776:PMC
768:doi
721:doi
675:doi
636:doi
593:doi
548:doi
515:PMC
507:doi
441:doi
369:EF5
194:EPA
147:CID
906::
884:.
874:.
862:10
860:.
856:.
833:.
825:.
813:46
811:.
807:.
784:.
774:.
764:45
762:.
758:.
735:.
727:.
717:41
715:.
691:.
683:.
671:49
669:.
665:.
642:.
632:27
630:.
607:.
599:.
589:30
587:.
564:.
554:.
523:.
513:.
503:45
501:.
497:.
472:53
470:.
447:.
437:64
435:.
405:.
892:.
868::
841:.
819::
792:.
770::
743:.
723::
699:.
677::
650:.
638::
615:.
595::
572:.
550::
531:.
509::
482:.
455:.
443::
386:-
384:F
340:Y
306:3
303:O
300:4
297:N
294:5
291:F
288:7
285:H
282:8
279:C
196:)
192:(
103:)
54:N
50:H
20:.
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.
